Metabolite

Celerion Announces Investment in ADME Suite of Services

Retrieved on: 
Wednesday, April 6, 2022
Metabolism, Family, Data management, Identification, Trial of the century, Cross-training (business), Friends, ADME, LINCOLN, Metabolite, Laboratory, Time, Pharmacy, CRO, Mark (given name), Biostatistics, Absorption, MIST, Patient, Pharmaceutical industry, Generic drug

LINCOLN, Neb., April 6, 2022 /PRNewswire/ -- Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has announced that it has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services to meet continuously increasing demand to conduct these studies. This investment includes expanding laboratory space, adding new capabilities as well as a dedicated customer service team.

Key Points: 
  • LINCOLN, Neb., April 6, 2022 /PRNewswire/ -- Celerion , a clinical research organization (CRO) to the biopharmaceutical industry, has announced that it has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services to meet continuously increasing demand to conduct these studies.
  • Celerion has invested in new state-of-the-art equipment and laboratory space to perform on-site scintillation counting allowing for radioactivity recovery results to be delivered in real-time.
  • What's more, this investment has also enabled Celerion to double capacity of lab throughput.
  • In addition to running human ADME studies, Celerion offers innovative metabolite identification and profiling .

908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows

Retrieved on: 
Wednesday, October 27, 2021
Technology, Biotechnology, Mobile, Wireless, Health, Other Health, Pharmaceutical, Other Science, Other Technology, Research, Medical Devices, General Health, Hardware, Science, Data Management, Molecule, Metabolomics, Void (law), Intel Corp. v. Advanced Micro Devices, Inc., Proteomics, Solvent, Medium (website), Research, Time, Poster, Mass spectrometry, American Society for Mass Spectrometry, Harvard Medical School, Ecosystem, Bioanalysis, DRS, Ligand Pharmaceuticals, Thermo Fisher Scientific, Metabolite, Chen Wen-chen, Drug discovery, Machine learning, Capillary electrophoresis, Intact, Microfluidics, Technology, MASS, ASMS, Selectivity, Company, COVID-19, CE-MS, CE, Dana–Farber Cancer Institute, Nasdaq, Rebel, Therapy, Oligonucleotide, Deubiquitinating enzyme, IMT, CTO, Society, Pharmaceutical industry, Fine chemical

Widely available genetic sequencing tools unlocked genomic knowledge and discovery, and it is widely acknowledged that the proteomics and metabolomics revolutions are next, said Dr. Christopher D. Brown, CTO and co-founder, 908 Devices.

Key Points: 
  • Widely available genetic sequencing tools unlocked genomic knowledge and discovery, and it is widely acknowledged that the proteomics and metabolomics revolutions are next, said Dr. Christopher D. Brown, CTO and co-founder, 908 Devices.
  • Bolstered by the remarkable success of rapid COVID-19 vaccine development, scientists are looking for more tools to accelerate discovery and development workflows.
  • Scott Mellors and Will Thompson, research scientists at 908 Devices, will present recent microfluidic prototype chip developments and associated analysis algorithm approaches for the companys ZipChip ecosystem in the proteomics and metabolomics application spaces.
  • 908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications.

Global Metabolomics Markets, Trends, Opportunity and Forecast Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, General Health, Health, Metabolism, Branches of biology, Systems biology, Biology, Omics, Metabolomics, Metabolite

The "Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Metabolomics refers to the large-scale study of metabolites, or small molecules, in cells, biofluids, tissues and organisms.
  • Key Questions Answered in This Report:
    How has the global metabolomics market performed so far and how will it perform in the coming years?
  • What is the structure of the global metabolomics market and who are the key players?

Changes in the blood metabolite profile are visible years before diagnosis of an alcohol-related disease

Retrieved on: 
Monday, October 19, 2020
Branches of biology, Psychoactive drugs, Medical specialties, Metabolism, RTT, Systems biology, Drinking culture, Cirrhosis, Metabolome, Liver, Metabolite, Alcohol

Alcohol is the cause underlying many severe diseases, such as alcohol dependence, liver cirrhosis and different types of cancer.

Key Points: 
  • Alcohol is the cause underlying many severe diseases, such as alcohol dependence, liver cirrhosis and different types of cancer.
  • The new study from the University of Eastern Finland discovered that changes in the serum metabolite profile are visible years before an individual is diagnosed with an alcohol-related disease.
  • Heavy alcohol use in itself was associated with considerable changes in the blood metabolite profile, e.g., in the levels of amino acids, steroid hormones and fatty acids.
  • Changes in Circulating Metabolome Precede Alcohol-Related Diseases in Middle-Aged Men: A Prospective Population-Based Study with a 30-Year Follow-Up

Global Metabolomics Market to 2025 - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Health, Other Health, Metabolism, Branches of biology, Biology, Systems biology, Omics, Metabolomics, Metabolite

The "Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • Metabolomics refers to the large-scale study of metabolites, or small molecules, in cells, biofluids, tissues and organisms.
  • Key Questions Answered in this Report:
    How has the global metabolomics market performed so far and how will it perform in the coming years?
  • What is the structure of the global metabolomics market and who are the key players?

Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model

Retrieved on: 
Monday, March 16, 2020
Amino acids, Branches of biology, Carboxylic acids, Hydroxyarenes, Metabolism, Intellectual disability, Phenylketonuria, RTT, Neurotransmitter, Metabolite, Tyrosine, 5-Hydroxyindoleacetic acid

The data also demonstrated a concomitant increase in tyrosine (Tyr), a metabolite of Phe and precursor to neurotransmitters, indicating enzymatic activity.

Key Points: 
  • The data also demonstrated a concomitant increase in tyrosine (Tyr), a metabolite of Phe and precursor to neurotransmitters, indicating enzymatic activity.
  • Additionally, brain levels of Phe, 5-HIAA (downstream serotonin metabolite) and coat color were normalized, further indicating restoration of the Phe metabolic pathway.
  • We developed a robust preclinical data package for our investigational HMI-102 gene therapy, which supported the initiation of our ongoing Phase 1/2 pheNIX clinical trial for adults with PKU, stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.
  • These published data demonstrated that a single dose of HMI-102 was able to restore the normal biochemical pathway in the established PKU model on normal protein diet.

Abstrax Tech Announces Groundbreaking 3D Metabolite Fingerprinting Technology

Retrieved on: 
Tuesday, December 10, 2019
Plant communication, Terpene, Tech, Fingerprint, Metabolite, Branches of biology

IRVINE, Calif., Dec. 10, 2019 /PRNewswire-PRWeb/ -- Abstrax Tech , a leader in the study and production of botanical and cannabis-derived terpenes, announces the release of its groundbreaking 3D metabolite fingerprinting technology.

Key Points: 
  • IRVINE, Calif., Dec. 10, 2019 /PRNewswire-PRWeb/ -- Abstrax Tech , a leader in the study and production of botanical and cannabis-derived terpenes, announces the release of its groundbreaking 3D metabolite fingerprinting technology.
  • "We are thrilled to share this powerful, potentially paradigm-changing discovery with the world," says Max Koby, Founding Partner and Chief Executive Officer of Abstrax Tech.
  • Abstrax Tech will be unveiling the technology and an expansive collection of terpenes at MJBiZCon December 11-13 at booth number C4648.
  • Abstrax Tech is more than willing to discuss these events at MJBizCon, while showcasing its quickly expanding line of products.

Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS

Retrieved on: 
Wednesday, November 6, 2019
Psychoactive drugs, Drugs, Receptor agonists, Metabolite, Metabolic pathway, MDMA, Metabolism

"Results from this human mass balance study confirm that etrasimod is slowly and extensively metabolized via multiple metabolic pathways and demonstrate no exposure from any major metabolites.

Key Points: 
  • "Results from this human mass balance study confirm that etrasimod is slowly and extensively metabolized via multiple metabolic pathways and demonstrate no exposure from any major metabolites.
  • "These highly favorable PK properties of etrasimod support the best-in-disease safety demonstrated in the Phase 2 OASIS study results.
  • This poster is among the few selected top presentations to be featured at an AAPS Special Poster Collections event.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

The metabolomics market was valued at USD 1,637.43 million in 2018, and is expected to reach USD 3,565.82 million by 2024

Retrieved on: 
Wednesday, September 11, 2019
Metabolism, Branches of biology, Biology, Metabolomics, Metabolite, Omics

The metabolomics market was valued at USD 1,637.43 million in 2018, and is expected to reach USD 3,565.82 million by 2024.

Key Points: 
  • The metabolomics market was valued at USD 1,637.43 million in 2018, and is expected to reach USD 3,565.82 million by 2024.
  • Metabolomics represent a systematic study of unique chemical processes inside the cells, which involve metabolites.
  • These are funded by several private and public funding, which helps in the growth of the metabolomics market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Global Metabolomics Market Outlook to 2023: Projected to Record a CAGR of Approx 12% - Rising Demand for Early & Accurate Diagnosis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 6, 2019
Health, Biotechnology, Metabolism, Branches of biology, Biology, Metabolomics, Omics, Metabolite

The "Global Metabolomics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Metabolomics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The metabolomics market will register a CAGR of nearly 12% by 2023.
  • New techniques in metabolomics are gaining widespread popularity among scientists and researchers due to their increased potential for fast and simultaneous fingerprinting of a vast number of metabolites.
  • In recent years, the field of metabolomics has shown significant potential in early disease diagnosis, therapy monitoring, and understanding the pathogenesis of different diseases.